17:56 , May 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Rett syndrome Patient sample and mouse studies suggest inhibiting GSK3B could help treat Rett syndrome. In postmortem cerebellum tissue samples from Rett syndrome patients, levels of GSK3B were higher than in samples from unaffected subjects....
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing fibroblast...
13:32 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Fate reports Phase I data for Fate-NK100 in ovarian cancer

Fate Therapeutics Inc. (NASDAQ:FATE) reported data from two evaluable patients with ovarian cancer in the Phase I APOLLO trial showing that Fate-NK100 led to stable disease with evidence of tumor reduction at day 28 in...
22:36 , Apr 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other molecule...
17:46 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

AMO Pharma reports Phase II data for myotonic dystrophy candidate

AMO Pharma Ltd. (Surrey, U.K.) reported data from a Phase II trial in 16 patients ages 13-34 with congenital or childhood-onset myotonic dystrophy type 1 (DM1) showing that tideglusib (AMO-02) was generally well tolerated with...
23:10 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; autoimmune disease

INDICATION: Solid tumors; Crohn’s disease; inflammatory bowel disease (IBD) In vitro, cell culture and mouse studies suggest inhibiting CDK9 and GSK3 could help treat cancer, Crohn’s disease and ulcerative colitis. Chemical synthesis and in vitro kinase...
17:35 , Mar 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) In vitro, cell culture and mouse studies identified a pyrazolo-tetrahydroquinolinone-based GSK3A inhibitor that could help treat AML. Chemical synthesis, in vitro activity and HEK cell-based binding assays of pyrazolo-tetrahydroquinolinone analogs yielded...
23:11 , Mar 7, 2018 |  BC Extra  |  Preclinical News

Selectively inhibiting GSK3's double genes for AML

Researchers at the Broad Institute of MIT and Harvard and colleagues found a way to design highly selective glycogen synthase kinase 3 inhibitors that target one of two forms of the gene. The approach could...
19:00 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Fate reports initial Phase I data for Fate-NK100 in AML

Fate Therapeutics Inc. (NASDAQ:FATE) reported preliminary data from 2 patients with relapsed or refractory acute myelogenous leukemia (AML) in the Phase I VOYAGE trial evaluating single doses of IV Fate-NK100. At day 14, a patient...
13:53 , Oct 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma; melanoma Mouse studies suggest inhibiting GSK3 could help treat lymphoma and melanoma. In a mouse model of lymphoma, a GSK3 inhibitor tool compound decreased tumor growth and increased survival compared with no treatment, and...